# Acute Myeloid Leukemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/acute-myeloid-leukemia

> 4 upcoming FDA catalysts in acute Myeloid Leukemia: apg-2575(lisaftoclax , AAPG) on May to Aug 2028 (topline data readout); apg-2575(lisaftoclax , AAPG) on May 2028 (primary completion); hmpl-306 regimen (HCM) on Dec 2028 to Mar 2029 (topline data readout); hmpl-306 regimen (HCM) on December 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q4 2024 | [Tambiciclib interim data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS | Acute Myeloid Leukemia | scheduled | "Based on a detailed analysis of all unblinded data, the IDMC projected that the interim analysis (60 events) will occur in the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm)) |
| November 20, 2024 | [ONUREG (azacitidine) trial start](https://sec-api.dev/pdufa/azacitidine) | APVO | Acute Myeloid Leukemia | completed | "Seattle, Washington, November 20, 2024 - Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today expanded on the potential of mipletamig, currently being evaluated as frontline therapy for the treatment of Acute Myeloid Leukemia (AML), in combination with standard of care venetoclax and azacitidine, noting the first patient dosed in the ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the overall efficacy trend seen in prior studies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017024129018/apvo-ex99_1.htm)) |
| Q4 2025 | [Annamycin interim data readout](https://sec-api.dev/pdufa/annamycin) | MBRX | acute myeloid leukemia | scheduled | "Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/ex_848453.htm)) |
| December 2025 | [Galinpepimut-s primary completion](https://sec-api.dev/pdufa/galinpepimut-s) | SLS | Acute Myeloid Leukemia | delayed | "NCT04229979 (Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Sellas Life Sciences Group." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04229979)) |
| 1H 2026 | [Annamycin interim data readout](https://sec-api.dev/pdufa/annamycin) | MBRX | acute myeloid leukemia | scheduled | "1H 2026 - Interim efficacy and safety data (n=~75-90) unblinded and Optimum Dose set for MIRACLE trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/ex_851330.htm)) |
| May to Aug 2028 | [Apg-2575(lisaftoclax ) topline data readout](https://sec-api.dev/pdufa/apg-2575-lisaftoclax) | AAPG | Acute Myeloid Leukemia | scheduled | "NCT06389292 (A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-25 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389292)) |
| May 2028 | [Apg-2575(lisaftoclax ) primary completion](https://sec-api.dev/pdufa/apg-2575-lisaftoclax) | AAPG | Acute Myeloid Leukemia | scheduled | "NCT06389292 (A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-25 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389292)) |
| Dec 2028 to Mar 2029 | [Hmpl-306 regimen topline data readout](https://sec-api.dev/pdufa/hmpl-306-regimen) | HCM | Acute Myeloid Leukemia | scheduled | "NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387069)) |
| December 2028 | [Hmpl-306 regimen primary completion](https://sec-api.dev/pdufa/hmpl-306-regimen) | HCM | Acute Myeloid Leukemia | scheduled | "NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387069)) |

## Drugs

- [Tambiciclib](https://sec-api.dev/pdufa/tambiciclib) (SLS)
- [ONUREG (azacitidine)](https://sec-api.dev/pdufa/azacitidine) (BMY)
- [Annamycin](https://sec-api.dev/pdufa/annamycin) (MBRX)
- [Galinpepimut-s](https://sec-api.dev/pdufa/galinpepimut-s) (SLS)
- [Apg-2575(lisaftoclax )](https://sec-api.dev/pdufa/apg-2575-lisaftoclax) (AAPG)
- [Hmpl-306 regimen](https://sec-api.dev/pdufa/hmpl-306-regimen) (HCM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/acute-myeloid-leukemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Acute Myeloid Leukemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/acute-myeloid-leukemia

```bibtex
@misc{secapidev_indications_acute_myeloid_leukemia_20261116,
  title        = {Acute Myeloid Leukemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/acute-myeloid-leukemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_acute_myeloid_leukemia_20261116","title":"Acute Myeloid Leukemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/acute-myeloid-leukemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
